0001564590-22-020986.txt : 20220523 0001564590-22-020986.hdr.sgml : 20220523 20220523161049 ACCESSION NUMBER: 0001564590-22-020986 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220523 ITEM INFORMATION: Other Events FILED AS OF DATE: 20220523 DATE AS OF CHANGE: 20220523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 22951685 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 8-K 1 evok-8k_20220523.htm 8-K evok-8k_20220523.htm
false 0001403708 0001403708 2022-05-23 2022-05-23

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 23, 2022

 

EVOKE PHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

001-36075

 

20-8447886

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

420 Stevens Avenue, Suite 370

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (858) 345-1494

(Former Name or Former Address, if Changed Since Last Report.)

 

Securities registered pursuant to Section 12(b) of the Exchange Act

 

 

 

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock,
par value $0.0001 per share

EVOK

The Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 


 

 

Item 8.01     Other Events.  

On May 23, 2022, Evoke Pharma, Inc. (“Evoke” or the “Company”) announced the presentation of the results of a retrospective analysis of United States administrative claims data that examined the association between metoclopramide-induced tardive dyskinesia (TD) and potential risk factors at the annual Digestive Disease Week Meeting (DDW 2022) taking place in San Diego, California from May 21-24, 2022.

 

The Company’s product, GIMOTI, is an FDA-approved novel nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Non-oral delivery is an important treatment option as gastroparesis causes oral medications to be unpredictably absorbed and vulnerable to one of the key symptoms of the disease, vomiting.

 

The approved labeling for Gimoti includes a black box warning regarding the risks of TD, a serious movement disorder that is often irreversible, associated with metoclopramide. Previous publications have suggested a strong causal relationship between metoclopramide and TD and reported varying frequencies of TD with metoclopramide use (from 1% to 15%). These reviews are largely outdated, have small sample sizes and different outcome definitions.

 

Selected as a poster of distinction during DDW 2022, the presentation titled “Revisiting the Risk of Tardive Dyskinesia with Metoclopramide Use: A Real-World Data Driven Epidemiology Study From 2011-2021” is the largest, most robust examination ever conducted to understand the risk of TD. The retrospective analysis was conducted with administrative claims data representing approximately 35% of the US population using the Truven Health MarketScan® Commercial Database. The data gathered between January 1, 2011 and December 31, 2020, comprised an excess of 300 unique employers, 25 different health plans, and 240 million covered lives studying patients with at least twelve (12) months of enrollment in a health insurance plan. Risk ratios were utilized to gauge the association between TD and renal dysfunction, diagnosis of mental health disorders, dopamine receptor blocking agents (DRBA) use, and diabetes. Results of the study concluded that TD is rare among metoclopramide-treated patients, with an incidence of 33.4 per 100,000, and among metoclopramide-treated gastroparesis patients, it was 98.8 per 100,000. In addition, age and sex appear to be significant risk factors for TD, with the highest TD incidence reported among elderly females. Additional risk factors for TD include renal dysfunction, coadministration of DRBAs, diagnosis of mental health disorders, and diabetes. The incidence of TD was also found to increase with prolonged metoclopramide use, with the greatest risk of TD observed after 24 to 48 months of chronic metoclopramide use.

 

Safe Harbor Statement

 

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: the potential benefits of GIMOTI for patients with diabetic gastroparesis. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: the data from a retrospective analysis may not be as robust as data from a controlled clinical trial and such data does not otherwise effective the black box warning on the Gimoti label related to TD; Evoke’s ability to obtain additional financing as needed to support its operations; the COVID-19 pandemic may continue to disrupt Evoke’s and EVERSANA’s business operations impairing the ability to commercialize GIMOTI and Evoke’s ability to generate any product revenue; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

May 23, 2022

 

EVOKE PHARMA, INC.

 

 

 

 

 

 

 

By:  /s/ Matthew J. D’Onofrio          

 

 

        Matthew J. D’Onofrio

    

 

        Executive Vice President,

 

 

        Chief Business Officer and Secretary

 

 

 

 

 

 

 

EX-101.SCH 2 evok-20220523.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 evok-20220523_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 4 evok-20220523_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 23, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 23, 2022
Entity Registrant Name EVOKE PHARMA, INC.
Entity Central Index Key 0001403708
Entity Emerging Growth Company false
Entity File Number 001-36075
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8447886
Entity Address, Address Line One 420 Stevens Avenue
Entity Address, Address Line Two Suite 370
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code (858)
Local Phone Number 345-1494
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock,par value $0.0001 per share
Trading Symbol EVOK
Security Exchange Name NASDAQ
XML 6 evok-8k_20220523_htm.xml IDEA: XBRL DOCUMENT 0001403708 2022-05-23 2022-05-23 false 0001403708 8-K 2022-05-23 EVOKE PHARMA, INC. DE 001-36075 20-8447886 420 Stevens Avenue Suite 370 Solana Beach CA 92075 (858) 345-1494 Common Stock,par value $0.0001 per share EVOK NASDAQ false false false false false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports evok-8k_20220523.htm evok-20220523.xsd evok-20220523_lab.xml evok-20220523_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "evok-8k_20220523.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "evok-8k_20220523.htm" ] }, "labelLink": { "local": [ "evok-20220523_lab.xml" ] }, "presentationLink": { "local": [ "evok-20220523_pre.xml" ] }, "schema": { "local": [ "evok-20220523.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "evok", "nsuri": "http://www.evokepharma.com/20220523", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220523.htm", "contextRef": "C_0001403708_20220523_20220523", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220523.htm", "contextRef": "C_0001403708_20220523_20220523", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220523/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-22-020986-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-020986-xbrl.zip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